Purpose. e aims of this study were to examine novel mutations in PITX2 and FOXC1 in Chinese patients with anterior segment dysgenesis (ASD) and to compare the clinical presentations of these mutations with previously reported associated phenotypes. Methods. Twenty-six unrelated patients with different forms of ASD were enrolled from our paediatric and genetic eye clinic. e ocular manifestations of both eyes of each patient were recorded. Genomic DNA was prepared from venous leukocytes. All coding exons of PITX2 and FOXC1 were amplified by polymerase chain reaction (PCR) from genomic DNA and subjected to direct DNA sequencing. Analysis of mutations in control subjects was performed by heteroduplex single-strand conformation polymorphism (SSCP) analysis. Results. Sequence analysis of the PITX2 gene revealed four mutations, including c.475_476delCT (P.L159VfsX39), c.64C > T (P.Q22X), c.296delG (P.R99PfsX56), and c.206G > A (P.R69H). e first three mutations were found to be novel. e c.475_476delCT (P.L159VfsX39) mutation, located at the 3′ end of the PITX2-coding region, was identified in a Chinese Axenfeld-Rieger syndrome (ARS) patient who presented with an unusual severe phenotype of bilateral aniridia. e clinical characteristics, including the severity and manifestations of the patient's phenotype, were compared with reported PITX2-associated aniridia phenotypes of ARS in the literature. Conclusions. ese results expand the mutation spectrum of the PITX2 gene in patients with ARS. e PITX2 gene may be responsible for a significant portion of ARS with additional systemic defects in the Chinese population. is is the first reported case of a mutation at the 3′ end of the PITX2-coding region extending the phenotypic consequences to bilateral aniridia. e traits of ARS could display tremendous variability in severity and manifestations due to the dominant-negative effect of PITX2. Our results further emphasize the importance of careful clinical and genetic analysis in determining mutation-disease associations and may lead to a better understanding of the role of PITX2 in ocular development.
Introduction
Anterior segment dysgenesis (ASD) encompasses a wide variety of developmental conditions in which multiple tissues, such as the cornea, iris, and lens, are affected [1] . ASD is classified into the following subtypes: Axenfeld-Rieger syndrome (ARS), aniridia, Peters anomaly (PA), and iridogoniodysgenesis. ARS is a rare multisystem autosomaldominant disorder with a prevalence of approximately 1 in 200,000 [2] and is characterized by complete penetrance but variable expressivity. Ocular phenotypes are mainly characterized by ASD of the eye, such as iris hypoplasia (IH), a prominent Schwalbe line, adhesion of the iris and cornea, corectopia, polycoria, and corneal opacity.
e various systemic features observed in ARS patients include facial dysmorphisms, dental anomalies, and redundant periumbilical skin.
ARS can be caused by mutations in the pituitary homeobox 2 (PITX2; OMIM601542) and forkhead box C1 (FOXC1; OMIM601090) genes. Mutations in these two genes are estimated to explain ∼40% of ARS [3] . e PITX2 gene produces three major protein-coding isoforms (PITX2a, PITX2b, and PITX2c), with each containing an identical homeodomain (HD) and C-terminal domain, differing only at the N-terminal region.
e common C-terminal domain contains a highly conserved 14-amino acid otp, aristaless, and rax (OAR) domain that mediates PITX2 protein interactions. e human PITX2 mutations identified to date cluster in the HD and C-terminal regions and mainly result in complete or partial loss of function. Dominant-negative and gain-of-function mutations have also been reported but represent an apparent minority [4] [5] [6] . Mutations in the PITX2 gene appear more likely to be associated with ocular, dental, and umbilical anomalies, whereas mutations in FOXC1 appear to be associated with isolated ocular or ocular, heart, and/or hearing defects. FOXC1 mutations primarily result in complete or partial loss of function, and duplications of FOXC1 have also been reported. Aniridia is a rare congenital disorder of either partial or complete hypoplasia of the iris and can be associated with other eye defects, such as corneal opacification, cataract, glaucoma, lens dislocation, ciliary body hypoplasia, foveal hypoplasia, strabismus, and nystagmus [7] . At least 90% of aniridia cases are caused by heterozygous loss-of-function mutations in PAX6 [8] . Rarely, isolated aniridia is caused by mutations in FOXC1 or PITX2.
Mutations in the PAX6, PITX2, and FOXC1 genes have been associated with ARS and aniridia in an autosomaldominant manner [9] [10] [11] [12] . e traits of ARS display wide ranges of variability in severity and manifestations. e severity of ARS phenotypes and the levels of normal PITX2 protein are also correlated [6, 13, 14] . ARS may be misdiagnosed as aniridia or iridocorneal endothelial syndrome (ICE syndrome) based on certain similarities of clinical characteristics. Furthermore, genetic studies and clinical descriptions of Chinese patients with ARS are nearly absent [15] [16] [17] . In this manuscript, PITX2 and FOXC1 mutation analysis and detailed clinical evaluations were performed to identify novel mutations and to characterize an unusual ophthalmic phenotype of severe ARS in a Chinese patient.
Methods

Patients.
Twenty-six unrelated patients with different forms of ASD, with or without nonocular defects, were recruited into our study. Anterior segment phenotypes included 5 patients with ARS, 1 patient with a phenocopy of aniridia, and 20 patients with other ASDs (primarily PA); 5 patients had an affected family member (2 with ARS and 3 with other ASDs). Classical aniridia patients with foveal hypoplasia and nystagmus were excluded. Furthermore, 100 normal controls, mainly from Southern China, participated in our study. All participants were enrolled from the Paediatric and Genetic Clinic, Eye Hospital, Zhongshan Ophthalmic Center, Guangzhou, China. Medical and ophthalmic histories were obtained. Ophthalmological examinations were performed by Drs. Guo and Zhang. e anterior and posterior segments of the eyes were documented by slit-lamp examination, specular microscopy, gonioscopy, applanation tonometry, A/B ultrasound scanning, and fundoscopy. Informed consent conforming to the tenets of the Declaration of Helsinki was obtained from each participant prior to the study.
Genetic Analysis.
Genomic DNA was extracted from venous blood from each participating individual. Prior to this study, the DNA of these patients had been screened for mutations in PAX6, but none of the tests were positive [18] . All coding regions of PITX2 and FOXC1 were amplified by polymerase chain reaction (PCR) using primers. e primer sequences are listed in Table 1 . e primers for exon 4 of PITX2a were adapted from those described by Cella and coworkers [19] . e PCR products were sequenced with an ABI BigDye Terminator cycle sequencing kit version 3.1 (Applied Biosystems, Foster City, CA) according to the manufacturer's recommendations using an ABI sequencer 3100 that was confirmed by our laboratory. For clarity, we studied the PITX2a isoform for mutations in affected patients. Sequencing results from the patients as well as consensus sequences from the NCBI human genome database (PITX2a; NM_153427.1 and FOXC1; NM_001453.2) were imported into the SeqManII program of the Lasergene package (DNASTAR Inc., Madison, Wisconsin) and were aligned to identify variations. Each variation was confirmed by bidirectional sequencing. Mutations were named according to the nomenclature recommended by the Human Genomic Variation Society (HGVS).
Heteroduplex Single-Strand Conformation Polymorphism
Analysis.
e variations detected in PITX2 and FOXC1 were further evaluated in 100 normal controls by heteroduplex single-strand conformation polymorphism (HA-SSCP) analysis, as previously described [20] , using additional pairs of primers (Table 1) . Briefly, the PCR product was mixed with an equal volume of gel-loading buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol), denatured at 95°C for 5 min and immediately placed on ice for 5 min. e DNA samples were loaded directly onto 8% polyacrylamide gels and run for 8 h at 40 W in a solution of 0.5 × TBE at room temperature.
Results
PITX2 mutations were found in four of twenty-six independent patients with ARS ( Figure 1 ). Of the four cases, three were novel. Each variation was confirmed by bidirectional sequencing. None of the novel variations were observed in other relatives or normal controls by HA-SSCP analysis ( Figure 2 ). Examples of the anterior segment findings are shown in Figure 3 . e clinical features and mutations in patients with our PITX2 mutations are summarized in Table 2 . Systemic anomalies of patients are shown in Figure 4 . e four patients had a wide variety of nonocular manifestations, including mild craniofacial dysmorphism, dental anomalies, and redundant periumblical skin, typical for ARS. A total of twenty-six affected individuals were molecularly assessed, and no FOXC1 mutations were detected.
It is of interest that significant differences were noted in the phenotypes of the two eyes of Patient 1. All patients had typical ocular characteristics of Axenfeld-Rieger syndrome in both eyes, except for Patient 1, who presented with Patient 1 (c.475_476delCT; P.L159VfsX39): the patient was a thirteen-year-old female with a high myopia of −6.50D in both eyes who presented at three years of age with hazy megalocornea, bilateral posterior polar cataracts, and earlyonset severe glaucoma and was diagnosed with aniridia by a local ophthalmologist (Figure 3(a) ). e patient's bestcorrected visual acuity was counting fingers in both eyes. e cornea was opaque, which was associated with an elevated normal intraocular pressure (IOP) resistant to medication. Endothelial cell counts were 1386 and 1518 in the right and left eyes, respectively. She had posterior embryotoxon in both eyes with broad iris adhesions. Significant findings were noted as the ocular examination displayed different degrees of aniridia in both eyes. e IOPs were 47 mmHg in the right eye and 39 mmHg in the left eye.
e anterior chamber appeared extremely shallow with a depth of 1.76 mm in the right eye and 1.91 mm in the left eye. A-scanning demonstrated posterior staphyloma with axial lengths of 25.56 mm in the right eye and 26.06 mm in the left eye. Funduscopy and type-B ultrasound were performed for this patient, and vitreous opacity and foveal hypoplasia were observed. Optic disc examination revealed a cup/disc ratio of 0.90 and showed glaucomatous atrophy of the optic nerve in both eyes (Figures 5(a) and 5(b) ). She had hearing defects, missing and misshapen teeth, and midface abnormalities (Figure 4) , and foveal hypoplasia was observed, but she did not have nystagmus and, therefore, did not have the classic manifestation features of true aniridia. Because of these findings, she was diagnosed as Axenfeld-Rieger Syndrome. e patient's visual acuity was poor, although trabeculotomies were performed in both eyes. e patient had no recorded family history of ocular disease.
Of the four mutations described, two were frame-shift mutations. e frame-shift mutation c.475_476delCT was predicted to produce a premature stop codon at position 197. A truncated protein with 196 amino acids, including an aberrant 38-amino acid residue, was putatively generated; this protein is 75 amino acids shorter than the wild-type PITX2a protein, which possesses 271 amino acids. us, this mutation led to partial loss of the C-terminal domain of PITX2. e c.296delG (P.R99PfsX56) mutation identified in the present study is a novel deletion mutation in exon 6, which causes a frame shift after Arg98 of PITX2a, resulting in a premature stop codon at codon 154, leading to complete loss of the C-terminal domain of PITX2. e nonsense mutation c.64C > T (P.Q22X) resulted in a substitution of glutamine for the stop codon at amino acid position 22, which is located in the N-terminal domain and results in premature termination with complete loss of the HD and C-terminal domain. Hence, the Q22X mutation affects the structure and function of PITX2 and is expected to produce a functionally null allele. e c.206G > A (P.69R > H) mutation, resulting in the replacement of an arginine residue with a histidine at the 69th amino acid position, has been identified in different original patients; this study is the fifth report [21] [22] [23] [24] . is mutation appears in different ethnic groups, indicating that c.206G > A may be a hot-spot mutation.
Discussion
ARS is an autosomal-dominant disorder that can be caused by mutations in the FOXC1 and PITX2 genes. Compared with FOXC1 mutations, PITX2 mutations are more commonly associated with the extraocular systemic abnormalities of ARS. In our case, all PITX2-affected patients had extraocular abnormalities, including redundant periumbilical skin, midface abnormalities, and abnormal dental development. e frequency of FOXC1 gene mutations in patients with ARS ranges from 20% to 30%. No sequence alterations were detected in the FOXC1 gene in any ASD patients. Our results suggest that the PITX2 gene accounts for a significant portion of the Chinese ARS population with additional systemic defects. Such a result is consistent with previous studies in which mutations in the PITX2 gene appeared to be more strongly associated with ARS and extraocular findings.
ARS traits display tremendous variability in severity and manifestation. In this study, of particular note is the frameshift mutation, c.475_476delCT (P.L159VfsX39), located at the 3′ end of the coding region; this mutation was identified in a Chinese ARS patient. e patient exhibited a phenocopy of bilateral aniridia, in addition to the classic ARS ocular features. is case is the first report of a mutation at the 3′ end of the PITX2-coding region that extends the phenotypic consequences of PITX2 mutations to bilateral aniridia. Glaucoma was diagnosed in patients with our PITX2 mutations; however, the severities were different. Patient 1 was diagnosed with early-onset severe glaucoma when she was three years old. Severe, early-onset glaucoma is typically difficult to control, leading to almost complete optic nerve head damage and more devastating visual loss in both eyes. A correlation between the severity of ARS phenotypes and normal PITX2 protein levels was also noted. In the literature, only three cases of ARS with features of bilateral or unilateral aniridia with PITX2 mutations have been found. One case was affected by a splicing mutation that introduced a premature termination, and two other cases were affected by nonsense mutations. In 2000, Rahat Perveen first described a phenocopy of bilateral aniridia carrying a G-C 3′ splice site of intron 2; the patient had best-corrected visual acuities of 6/9 and 6/12 [25] . Véronique Vieira and coworkers identified an E55X nonsense mutation in an ARS patient who presented with complete aniridia associated with goniostrands in the right eye and major corectopia associated with partial aniridia in the left eye [26] . In 2012, Law et al. reported an asymmetric phenotype of the anterior segment with features of Axenfeld-Rieger anomaly in one eye, but aniridia in the other eye. A nonsense mutation, p.Q21X for PITX2a or p.Q67X for PITX2b, was found in patient M.A, who had best-corrected visual acuities of 20/80 in the right eye and 20/40 in the left eye [27] . PITX2a is a 33 kDa homeodomain protein.
e HD is responsible for recognizing specific DNA sequences to bring transcription factors to the appropriate target genes. e integrity of PITX2 is essential for binding DNA and is critical for PITX2 to act as a transcription factor [28] . All of the above-reported mutations were predicted to abolish the DNA-binding functions of the affected allele and to lead to a premature termination codon (PTC) and are subject to nonsense-mediated mRNA decay (NMD).
e mechanism for the PITX2-related severity of the ocular phenotype in these patients may be the consequence of PITX2 haploinsufficiency. ese mutations lead to severe aniridia-emulating phenotypes but result in a relatively good visual acuity. In this study, the P.L159VfsX39 mutation is a novel deletion mutation at the 3′ end of the PITX2-coding region, encoding a normal HD but partially Journal of Ophthalmology truncating the PITX2 C-terminus, which causes a frame shift after Pro158 of PITX2a and introduces a PTC in exon 6. As this PTC is located in the final exon of the gene, it is predicted to escape NMD. Many researchers have noted that aniridia phenotypes are caused by mutations that introduce a PTC; however, they have also suggested that 3′ mutations, which introduce a PTC into the PAX6 open reading frame, do in fact yield dominant-negative alleles that may cause more severe phenotypes [29, 30] . Until now, there have been only 2 reports of PITX2 dominant-negative mutations that have been characterized at the cellular level [5, 14, 31] . Saadi et al. have noted that lysine at residue 50 in the PITX2 HD plays important roles in both DNA-binding and dimerization activities. e authors also suggested that dimerization appears to involve both the C-terminal region and the HD, as exemplified by the dominant-negative PITX2 K88E protein [4] . Unlike previously reported PITX2-associated aniridia mutations, this P.L159VfsX39 frame-shift mutation retained the position 50 residue of this HD. erefore, we predicted that the truncating mutation at the 3′ end of PITX2, P.L159VfsX39, escapes NMD and generates dominant-negative proteins that cause much more severe phenotypes than the abovementioned PITX2 mutations. e PITX2 C-terminus has both inhibitory and stimulatory activities [4] . Irfan Saadi and colleagues reported that the PITX2 mutations at the 3′ part of the coding region, W133Stop and D122FS, may result in gain-of-function phenotypes in ARS patients at the cellular level [4, 32] . One caveat of this interpretation is that the mutants may not be expressed in patients because of nonsense-mediated mRNA decay or protein degradation.
ese results indicate the complexity and potential ramifications of mutations in the PITX2 C-terminal tail in ARS patients. Hopefully, additional research in this area may eventually clarify the exact mechanism of these mutations.
e iris manifestations in ASDs are important in making a diagnosis. Clinically, ARS may be confused with ICE syndrome or aniridia on the basis of clinical similarities. In our case, for instance, Patient 1 was originally diagnosed with aniridia, and foveal hypoplasia was observed, but she did not have nystagmus and, therefore, did not have the classic manifestations of true aniridia. Patient 4 was misdiagnosed with ICE syndrome; specular microscopy showed reduced endothelial densities but normal morphology, which is inconsistent with ICE syndrome (Figure 6 ). For patients presenting with IH and glaucoma, careful evaluations of endothelial morphology, iris, fundus, foveal development, and extraocular manifestations are critical.
In summary, we expanded the mutation spectrum of the PITX2 gene in individuals with ARS. Our results suggest that the PITX2 gene accounts for a significant portion of the Chinese ARS population with systemic abnormalities. is study is the first reported case of a mutation at the 3′ end of the PITX2-coding region that extends the phenotypic consequences of PITX2 mutations to bilateral aniridia. erefore, we speculated that ARS traits can display tremendous variability in severity and manifestation for the PITX2 dominant-negative effect. ese results further emphasize the importance of careful clinical and genetic analysis and lead to a better understanding of the role of PITX2 in the normal development of the eye.
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